VEGFA and peritoneum cancer: Interestingly, a randomized phase II trial at Roswell Park Comprehensive Cancer Center is currently testing the effect of pegcetacoplan when given in combination with the programmed death-1 (PD-1) inhibitor pembrolizumab, or when given in combination with pembrolizumab plus bevacizumab, an inhibitor of vascular endothelial growth factor (VEGF), in patients with ovarian, fallopian tube, or primary peritoneal cancer.